SNDX
Syndax Pharmaceuticals, Inc. · Healthcare
Insiders sold $2.7M of Syndax Pharmaceuticals, Inc. in the last 12 months and bought none
SNDX over the last year
SNDX after insider buys
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
61 insider filings since 2016, newest first
Michael A Metzger · Chief Executive Officer
Nicholas A.j. Botwood · Head of R&D, CMO
Michael A Metzger · Chief Executive Officer
Keith A. Goldan · CFO
Michael A Metzger · CEO
Keith A. Goldan · CFO
Michael A Metzger · CEO
Nicholas A.j. Botwood · Head of R, D, CMO
Martin H. Huber Jr. · Director
Keith Katkin · Director
Keith A. Goldan · CFO
Briggs Morrison · Director
William Meury · Director
Briggs Morrison · Director
Briggs Morrison · Director
Briggs Morrison · Director
Briggs Morrison · Director
Briggs Morrison · Pres, Head of R, D
Peter Ordentlich · Chief Scientific Officer
Michael A Metzger · CEO
Briggs Morrison · Pres, Head of R, D
Pierre Legault · Director
Peter Ordentlich · Chief Scientific Officer
Keith Katkin · Director
Michael A Metzger · CEO
Keith Katkin · Director
Michael A Metzger · CEO
Briggs Morrison · Pres, Head of R, D
Briggs Morrison · Pres, Head of R, D
Dennis Podlesak · Director
Peter Ordentlich · Chief Scientific Officer
Michael A Metzger · CEO
Michael A Metzger · CEO
Briggs Morrison · Pres, Head of R, D
Briggs Morrison · Pres, Head of R, D
Pierre Legault · Director
Briggs Morrison · CEO
Michael A Metzger · President and COO
Michael A Metzger · President and COO
Fabrice Egros · Director
Michael A Metzger · President and COO
Michael A Metzger · President and COO
Michael A Metzger · President and COO
Briggs Morrison · CEO
Michael A Metzger · President and COO
Fabrice Egros · Director
Fabrice Egros · Director
Dennis Podlesak · Director
Fabrice Egros · Director
Briggs Morrison · CEO
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.